Intravitreal connective tissue growth factor neutralizing antibody or bevacizumab alone or in combination for prevention of proliferative vitreoretinopathy in an experimental model.

摘要: Abstract Connective tissue growth factor (CTGF) is released by retinal pigment epithelial (RPE) cells and detectable in proliferative membranes (PrMs). This experimental study was performed to investigate the mRNA protein levels of both CTGF vascular endothelial A (VEGF-A) a rabbit model vitreoretinopathy (PVR). In addition, effects single intravitreal injection safe dose anti-CTGF or bevacizumab as monotherapy combination were evaluated. PVR induced right eye albino rabbits cultured adult human RPE cells. Quantitative real-time reverse transcription PCR (qRT-PCR) Western blot analysis VEGF-A on whole versus controls at different time points. next step, models assigned five groups. The groups received 0.1 ml 100 μg/ml (final concentration 6.6 μg/ml vitreous) 0.03 ml 25 mg/ml bevacizumab. combined group, abovementioned amounts injected intravitreally from separate sites one session. No antibody control group. Intravitreal IgG (1 mg/ml isotype matched) placebo After 2 weeks, histologic evaluation including, trichrome staining for collagen, immunostaining anti-alpha-smooth muscle actin myofibroblasts, anti-collagen type-1 paraffin embedded anterior-posterior sections done. fundus photography clinically equivalent staging. Twenty-four hours following induction, increased five- and- three-fold compared controls, respectively (P